Novanta (NOVT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 29, 2025, to be held virtually, allowing shareholders to vote and ask questions online.
Key proposals include election of nine directors, advisory approval of executive compensation, advisory vote on frequency of say-on-pay, and appointment of Deloitte & Touche LLP as auditor.
Shareholders of record as of April 15, 2025, are entitled to vote; proxy materials and annual report distributed starting April 25, 2025.
Voting matters and shareholder proposals
Proposals: elect nine directors, approve executive compensation (say-on-pay), determine frequency of future say-on-pay votes, appoint Deloitte as auditor, and address other business as needed.
Board recommends voting for all director nominees, for executive compensation, for annual say-on-pay, and for Deloitte as auditor.
Majority of votes cast required for approval of each proposal; cumulative voting applies for directors.
Shareholders can submit director nominations and proposals for future meetings, with specific deadlines and requirements.
Board of directors and corporate governance
Board set at nine members, eight of whom are independent; Chair and CEO roles are combined, with an independent Lead Director providing oversight.
Board committees: Audit, Compensation, and ESG, all comprised of independent directors.
Board and committees conduct annual self-evaluations; directors are encouraged to attend annual meetings.
Board diversity: 44% women or underrepresented groups; robust stock ownership and anti-hedging policies in place.
ESG Committee oversees director nominations, governance policies, sustainability, and cybersecurity.
Latest events from Novanta
- Record revenue and profit growth set up a strong 2026 outlook with robust acquisition plans.NOVT
Q4 202524 Feb 2026 - Q2 revenue up 2.8% to $236M, with medical growth offsetting weak industrial demand.NOVT
Q2 20242 Feb 2026 - Q3 2024 revenue up 10.3% to $244.4M, with acquisitions driving growth and flat organic sales.NOVT
Q3 202416 Jan 2026 - 2024 saw record cash flow, margin gains, and new products; 2025 targets 5% growth amid volatility.NOVT
Q4 202411 Dec 2025 - Q1 2025 delivered revenue growth, higher net income, and resilient guidance amid trade risks.NOVT
Q1 202528 Nov 2025 - Q2 2025 revenue up 2.2%, strong bookings, but operating income down 42% on higher costs.NOVT
Q2 202523 Nov 2025 - Q3 2025 saw higher revenue and adjusted EPS, but lower net income amid rising costs.NOVT
Q3 202513 Nov 2025